Camson Bio Technologies Limited announced unaudited standalone earnings results for the fourth quarter and full year and consolidated earnings results for the year ended march 31, 2018. For the quarter, on standalone basis, the company reported negative revenue from operations of INR 5.091 million compared with revenue of INR 11.401 million for the same period a year ago. Loss before exceptional items and tax and loss before tax was INR 49.032 million compared with INR 12.628 million for the same period a year ago. Loss for the period was INR 49.032 million or INR 1.63 per basic and diluted share compared with INR 12.628 million or INR 0.42 per basic and diluted share for the same period a year ago. For the full year, on standalone basis, the company reported revenue from operations of INR 193.105 million compared with INR 103.502 million for the same period a year ago. Loss before exceptional items and tax and was INR 112.171 million compared with INR 232.244 million for the same period a year ago. Loss before tax was INR 121.171 million compared with INR 232.244 million for the same period a year ago. Loss for the period was INR 112.171 million or INR 3.68 per basic and diluted share compared with INR 230.539 million or INR 7.64 per basic and diluted share for the same period a year ago. For the full year, on consolidated basis, the company reported revenue from operations of INR 193.105 million compared with INR 153.923 million for the same period a year ago. Loss before exceptional items and tax and was INR 112.171 million compared with INR 292.395 million for the same period a year ago. Loss before tax was INR 112.171 million compared with INR 321.593 million for the same period a year ago. Loss for the period was INR 112.171 million or INR 4.72 per basic and diluted share compared with INR 319.888 million or INR 11.31 per basic and diluted share for the same period a year ago.